-+ 0.00%
-+ 0.00%
-+ 0.00%

Tempus AI, Predicta Biosciences expand co-branded whole-genome sequencing assay access

PUBT·04/15/2026 12:31:17
Listen to the news
Tempus AI, Predicta Biosciences expand co-branded whole-genome sequencing assay access
  • Tempus AI entered collaboration with Predicta Biosciences to commercially expand co-branded GenoPredicta whole-genome sequencing assay for hematologic malignancies and measurable residual disease monitoring.
  • Partnership broadens access for Tempus Life Sciences partners to ultrasensitive workflow combining flow cytometry with WGS from peripheral blood or bone marrow.
  • Assay targets sensitivity down to 1 in 1,000,000 cells from as few as 50 tumor cells, supporting diagnosis, risk classification, and treatment-resistance tracking.
  • GenoPredicta has been clinically validated in multiple myeloma and other plasma cell dyscrasias, with other indications offered for research use only.
  • Tempus cited 100% concordance between peripheral blood and bone marrow results, positioning test as alternative to more invasive biopsies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260415412276) on April 15, 2026, and is solely responsible for the information contained therein.